In surprise decision, US approves muscular dystrophy drug - The Associated Press

1. In surprise decision, US approves muscular dystrophy drug  The Associated Press
2. Sarepta’s surprise FDA approval for rare disease drug excites investors  MarketWatch
3. Stocks To Watch With Stock Market At Record Highs Include Paycom Software  Investor's Business Daily
4. FDA OKs Golodirsen (Vyondys 53) for Duchenne Muscular Dystrophy  Medscape
5. Sarepta Stock Is Spiking as FDA Reverses Course, Approving Drug  Barron's
6. View full coverage on Google News

In surprise decision, US approves muscular dystrophy drug - The Associated Press
Read More


Bagikan Berita Ini